Human papillomavirus (‎HPV)‎ nucleic acid amplification tests (‎NAATs)‎ to screen for cervical pre-cancer lesions and prevent cervical cancer

16 March 2022
 | Policy brief
Human papillomavirus (‎HPV)‎ nucleic acid amplification tests (‎NAATs)‎ to screen for cervical pre-cancer lesions and prevent cervical cancer
Download (253.7 kB)

Overview

This policy brief focuses on the use of and the differences between HPV DNA-based and HPV 
mRNA-based molecular nucleic acid amplification tests (NAATs).

Related guidelines

WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition: use of mRNA tests for human papillomavirus (‎HPV)‎,  December 2021

WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, July 2021

WHO Team
Global HIV, Hepatitis and STIs Programmes (HHS), Sexual and Reproductive Health and Research (SRH)
Editors
World Health Organization
Number of pages
6
Reference numbers
ISBN: 978 92 4 004524 8
Copyright